Self-adjuvanting α-helical polypeptide simultaneously delivers neoantigen mRNAs and activates dendritic cells to eradicate tumors
T cells and PD-L1 by 4T1 tumor cells after polyplex treatment and further demonstrated the synergistic effect between polyplex vaccine and anti-PD-1 therapy. Our polyplex system provides a facile and generalizable approach to developing robust mRNA-based cancer vaccines.
Authors
- Tianrui Xue (ORCID: https://orcid.org/0000-0002-2485-7514)
- Abhisek Dwivedy (ORCID: https://orcid.org/0000-0001-9745-8138)
- Joonsu Han (ORCID: https://orcid.org/0000-0002-7794-0661)
- Rimsha Bhatta
- Yueji Wang
- Joseph Irudayaraj (ORCID: https://orcid.org/0000-0002-0630-1520)
- Bo Yang (ORCID: https://orcid.org/0000-0002-9723-2259)
- Xing Wang (ORCID: https://orcid.org/0000-0001-9930-3287)
- Hua Wang (ORCID: https://orcid.org/0000-0002-1157-8786)
- Jian Liu (ORCID: https://orcid.org/0000-0002-1447-0973)
- Qian Chen (ORCID: https://orcid.org/0000-0002-1968-441X)
- Shuming Nie
- Jiadiao Zhou
- Matthew Berry
- Yusheng Liu
- Xin Wang (ORCID: https://orcid.org/0000-0002-4122-8226)
- Daniel Nguyen
- Keith Bailey
Institutions
- Zhejiang International Studies University (CN)
- Alnylam Pharmaceuticals (United States) (US)
- University of Illinois Urbana-Champaign (US)
- Zhejiang University-University of Edinburgh Institute (CN)
Publication Details
- Journal
- Proceedings of the National Academy of Sciences
- Published
- 2026-04-15
- DOI
- https://doi.org/10.1073/pnas.2504976123
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- American Cancer Society
- Sontag Foundation
- National Cancer Institute
- Division of Materials Research
- Air Force Office of Scientific Research